{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:59:24Z","timestamp":1792166364840,"version":"4.4.0"},"reference-count":13,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,3,30]],"date-time":"2012-03-30T00:00:00Z","timestamp":1333065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> The combination of pegylated interferon (Peg\u2010IFN) and ribavirin is currently the gold standard therapy in patients with HCV chronic infection. The duration of therapy, as well as the therapeutic dosage, depend on the genotype. Identification of the genotype and rapid virological response (RVR) are widely accepted as the most important predictors of clinical outcome during antiviral therapy but to optimize cost\u2010benefits and to reduce possible side effects, further prognostic factors are needed. Squamous cell carcinoma antigens immunocomplex (SCCA\u2010IC) has been reported to be increased in the serum of patients with liver cancer. In this multicentric prospective study, we investigated the serum levels of SCCA\u2010IC in 103 patients with HCV chronic infection. Serum HCV\u2010RNA was detected before the beginning of treatment, after 4, 12, 24 or 48\u2003weeks, and at week 24 during follow\u2010up. RVR, early virological response and sustained virological response (SVR) were assessed following the international guidelines. SCCA\u2010IC levels were higher in responders (238\u2003AU, interquartile difference 130\u2013556\u2003AU) and decreased significantly to 125\u2003AU (70\u2013290\u2003AU). The mean baseline value in nonresponders was 149\u2003AU (86.5\u2013306.5\u2003AU), but after 4\u2003weeks of treatment the serum levels decreased to 115\u2003AU (80\u2013280\u2003AU): the profile of reduction was different between patients with or without a positive SVR. Logistic regression with SVR as dependent variable identified as significant independent variables: the reduction in SCCA\u2010IC after 1\u2003month (OR\u2003= 4.82; 95% CI 1.39\u201316.67; <jats:italic>P<\/jats:italic>\u2003=\u20030.131) and a genotype other than 1 (OR\u2003=\u20030.094; 95% CI 0.21\u20130.42; <jats:italic>P<\/jats:italic>\u2003=\u20030.002); sex and age were also significant factors influencing SVR. SCCA\u2010IC seems to be a reliable independent prognostic marker of therapeutic effectiveness in anti\u2010HCV positive patients undergoing antiviral therapy.<\/jats:p>","DOI":"10.1111\/j.1365-2893.2012.01604.x","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T12:19:03Z","timestamp":1333455543000},"page":"704-710","source":"Crossref","is-referenced-by-count":11,"title":["SCCA\u2010IC serum levels are predictive of clinical response in HCV chronic hepatitis to antiviral therapy: a multicentric prospective study"],"prefix":"10.1111","volume":"19","author":[{"given":"E.","family":"Fransvea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Trerotoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bernabucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mazzocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Renna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Angarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Antonaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Giannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,30]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.076646"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.10.032"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01217.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21106"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21908"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2006.05.007"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2007.05.014"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-200"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-8-29"},{"key":"e_1_2_8_14_2","first-page":"794","article-title":"Squamous cellular carcinoma immunocomplexed is increased in scleroderma patients with lung fibrosis","volume":"25","author":"Giannelli G","year":"2007","journal-title":"Clin Exp Rheumatol"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2893.2012.01604.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2893.2012.01604.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:44:57Z","timestamp":1695473097000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2893.2012.01604.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,30]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1111\/j.1365-2893.2012.01604.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2893.2012.01604.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,30]]}}}